Synthesis and biological evaluation of novel 3-(quinolin-4-ylamino)benzenesulfonamides as carbonic anhydrase isoforms I and II inhibitors

References

• (a) Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov 2008;7:168–81.,
   PubMed Web of Science ®Google Scholar
  (b) Alterio V, Di Fiore A, D’Ambrosio K, et al. Multiple binding modes of inhibitors to carbonic anhydrases: how to design specific drugs targeting 15 different isoforms? Chem Rev 2012;112:4421–68.,
   PubMed Web of Science ®Google Scholar
  (c) Supuran CT. Applications of carbonic anhydrases inhibitors in renal and central nervous system diseases. Expert Opin Ther Pat 2018;28:713–21.,
   PubMed Web of Science ®Google Scholar
  (d) Supuran CT. Carbonic anhydrase inhibitors and their potential in a range of therapeutic areas. Expert Opin Ther Pat 2018;28:709–12.,
   PubMed Web of Science ®Google Scholar
  (e) Supuran CT. Carbonic anhydrase inhibitors as emerging agents for the treatment and imaging of hypoxic tumors. Expert Opin Investig Drugs 2018;27:963–70.,
   PubMed Web of Science ®Google Scholar
  (f) Nocentini A, Supuran CT. Carbonic anhydrase inhibitors as antitumor/antimetastatic agents: a patent review (2008-2018). Expert Opin Ther Pat 2018;28:729–40.
   PubMed Web of Science ®Google Scholar
• (a) Supuran CT. Structure-based drug discovery of carbonic anhydrase inhibitors. J Enzyme Inhib Med Chem 2012;27:759–72.,
   PubMed Web of Science ®Google Scholar
  (b) De Simone G, Supuran CT. (In)organic anions as carbonic anhydrase inhibitors. J Inorg Biochem 2012;111:117–29.,
   PubMed Web of Science ®Google Scholar
  (c) Supuran CT. Carbonic anhydrase inhibition and the management of hypoxic tumors. Metabolites 2017;7:E48,
   PubMed Web of Science ®Google Scholar
  (d) Supuran CT. Carbonic anhydrases and metabolism. Metabolites 2018;8:E25.,
   PubMed Web of Science ®Google Scholar
  (e) Supuran CT. Carbon- versus sulphur-based zinc binding groups for carbonic anhydrase inhibitors? J Enzyme Inhib Med Chem 2018;33:485–95.
   PubMed Web of Science ®Google Scholar
• (a) Supuran CT. Carbonic anhydrase inhibitors. Bioorg Med Chem Lett 2010;20:3467–74.,
   PubMed Web of Science ®Google Scholar
  (b) Briganti F, Pierattelli R, Scozzafava A, Supuran CT. Carbonic anhydrase inhibitors. Part 37. Novel classes of carbonic anhydrase inhibitors and their interaction with the native and cobalt-substituted enzyme: kinetic and spectroscopic investigations. Eur J Med Chem 1996;31:1001–10.,
   Web of Science ®Google Scholar
  (c) Supuran CT. How many carbonic anhydrase inhibition mechanisms exist? J Enzyme Inhib Med Chem 2016;31:345–60.,
   PubMed Web of Science ®Google Scholar
  (d) Supuran CT. Advances in structure-based drug discovery of carbonic anhydrase inhibitors. Expert Opin Drug Discov 2017;12:61–88.,
   PubMed Web of Science ®Google Scholar
  (e) Supuran CT. Structure and function of carbonic anhydrases. Biochem J 2016;473:2023–32.,
   PubMed Web of Science ®Google Scholar
  (f) Neri D, Supuran CT. Interfering with pH regulation in tumours as a therapeutic strategy. Nat Rev Drug Discov 2011;10:767–77.,
   PubMed Web of Science ®Google Scholar
  (g) Supuran CT, Vullo D, Manole G, et al. Designing of novel carbonic anhydrase inhibitors and activators. Curr Med Chem Cardiovasc Hematol Agents 2004;2:49–68.
   PubMedGoogle Scholar
• (a) Pastorekova S, Parkkila S, Pastorek J, Supuran CT. Carbonic anhydrases: current state of the art, therapeutic applications and future prospects. J Enzyme Inhib Med Chem 2004;19:199–229.,
   PubMed Web of Science ®Google Scholar
  (b) Supuran CT, Capasso C. The eta-class carbonic anhydrases as drug targets for antimalarial agents. Expert Opin Ther Targets 2015;19:551–63.,
   PubMed Web of Science ®Google Scholar
  (c) Capasso C, Supuran CT. Bacterial, fungal and protozoan carbonic anhydrases as drug targets. Expert Opin Ther Targets 2015;19:1689–704.,
   PubMed Web of Science ®Google Scholar
  (d) Supuran CT, Capasso C. Biomedical applications of prokaryotic carbonic anhydrases. Expert Opin Ther Pat 2018;28:745–54.,
   PubMed Web of Science ®Google Scholar
  (e) Supuran CT, Capasso C. An overview of the bacterial carbonic anhydrases. Metabolites 2017;7:56.
   PubMed Web of Science ®Google Scholar
• (a) Supuran CT. Carbonic anhydrase inhibitors and activators for novel therapeutic applications. Future Med Chem 2011;3:1165–80.,
   PubMed Web of Science ®Google Scholar
  (b) Akocak S, Lolak N, Bua S, et al. Discovery of novel 1,3-diaryltriazene sulfonamides as carbonic anhydrase I, II, VII, and IX inhibitors. J Enzyme Inhib Med Chem 2018;33:1575–80.,
   PubMed Web of Science ®Google Scholar
  (c) Winum JY, Temperini C, El Cheikh K, et al. Carbonic anhydrase inhibitors: clash with Ala65 as a means for designing inhibitors with low affinity for the ubiquitous isozyme II, exemplified by the crystal structure of the topiramate sulfamide analogue. J Med Chem 2006;49:7024–31.,
   PubMed Web of Science ®Google Scholar
  (d) Supuran CT. Carbonic anhydrase inhibitors in the treatment and prophylaxis of obesity. Expert Opin Ther Pat 2003;13:1545–50.
   Web of Science ®Google Scholar
• (a) Carta F, Supuran CT. Diuretics with carbonic anhydrase inhibitory action: a patent and literature review (2005–2013). Expert Opin Ther Pat 2013;23:681–91.,
   PubMed Web of Science ®Google Scholar
  (b) da Silva Cardoso V, Vermelho AB, Ricci Junior E, et al. Antileishmanial activity of sulfonamide nanoemulsions targeting the β-carbonic anhydrase from Leishmania species. J Enzyme Inhib Med Chem 2018;33:850–7.,
   PubMed Web of Science ®Google Scholar
  (c) Akocak S, Lolak N, Vullo D, et al. Synthesis and biological evaluation of histamine Schiff bases as carbonic anhydrase I, II, IV, VII, and IX activators. J Enzyme Inhib Med Chem 2017;32:1305–12.,
   PubMed Web of Science ®Google Scholar
  (d) Supuran CT. Acetazolamide for the treatment of idiopathic intracranial hypertension. Expert Rev Neurother 2015;15:851–6.
   PubMed Web of Science ®Google Scholar
• Aggarwal M, Kondeti B, McKenna R. Anticonvulsant/antiepileptic carbonic anhydrase inhibitors: a patent review. Expert Opin Ther Pat 2013;23:717–24.
   PubMed Web of Science ®Google Scholar
• Kayser B, Dumont L, Lysakowski C, et al. Reappraisal of acetazolamide for the prevention of acute mountain sickness: a systematic review and meta-analysis. High Alt Med Biol 2012;13:82–92.
   PubMed Web of Science ®Google Scholar
• (a) Masini E, Carta F, Scozzafava A, Supuran CT. Antiglaucoma carbonic anhydrase inhibitors: a patent review. Expert Opin Ther Pat 2013;23:705–16.,
   PubMed Web of Science ®Google Scholar
  (b) Borras J, Scozzafava A, Menabuoni L, et al. Synthesis of water-soluble, topically effective intraocular pressure lowering aromatic/heterocyclic sulfonamide containing 8-quinoline-sulfonyl moieties: is the tail more important than the ring? Bioorg Med Chem 1999;7:2397–406.,
   PubMed Web of Science ®Google Scholar
  (c) Stanica L, Gheorghiu M, Stan M, et al. Quantitative assessment of specific carbonic anhydrase inhibitors effect on hypoxic cells using electrical impedance assays. J Enzyme Inhib Med Chem 2017;32:1079–90.,
   PubMed Web of Science ®Google Scholar
  (d) Abdoli M, Angeli A, Bozdag M, et al. Synthesis and carbonic anhydrase I, II, VII, and IX inhibition studies with a series of benzo[d]thiazole-5- and 6-sulfonamides. J Enzyme Inhib Med Chem 2017;32:1071–8.
   PubMed Web of Science ®Google Scholar
• (a) Fabrizi F, Mincione F, Somma T, et al. A new approach to antiglaucoma drugs: carbonic anhydrase inhibitors with or without NO donating moieties. Mechanism of action and preliminary pharmacology. J Enzyme Inhib Med Chem 2012;27:138–47.,
   PubMed Web of Science ®Google Scholar
  (b) Supuran CT. Carbonic anhydrase activators. Future Med Chem 2018;10:561–73.
   PubMed Web of Science ®Google Scholar
• Chiaramonte N, Bua S, Ferraroni M, et al. 2-Benzylpiperazine: a new scaffold for potent human carbonic anhydrase inhibitors. Synthesis, enzyme inhibition, enantioselectivity, computational and crystallographic studies and in vivo activity for a new class of intraocular pressure lowering agents. Eur J Med Chem 2018;151:363–75.
   PubMed Web of Science ®Google Scholar
• Egan TJ. Quinoline antimalarials. Expert Opin Ther Pat 2001;11:185–209.
   Web of Science ®Google Scholar
• Sangshetti JN, Khan FA, Kulkarni AA, et al. Antileishmanial drug discovery: comprehensive review of the last 10 years. Rsc Advanc 2015;5:32376–415.
   Web of Science ®Google Scholar
• Keri RS, Patil SA. Quinoline: a promising antitubercular target. Biomed Pharmacother 2014;68:1161–75.
   PubMed Web of Science ®Google Scholar
• Zajdel P, Marciniec K, Maślankiewicz A, et al. Antidepressant and antipsychotic activity of new quinoline-and isoquinoline-sulfonamide analogs of aripiprazole targeting serotonin 5-HT1A/5-HT2A/5-HT7 and dopamine D2/D3 receptors. Eur J Med Chem 2013;60:42–50.
   PubMed Web of Science ®Google Scholar
• R Solomon V, Lee H. Quinoline as a privileged scaffold in cancer drug discovery. Curr Med Chem 2011;18:1488–508.
   PubMed Web of Science ®Google Scholar
• (a) Afzal O, Kumar S, Haider MR, et al. A review on anticancer potential of bioactive heterocycle quinolone. Eur J Med Chem 2015;97:871–910.,
   PubMed Web of Science ®Google Scholar
  (b)Lenoci A, Tomassi S, Conte M, et al. Quinoline A ‐based p300 histone acetyltransferase inhibitors with pro‐apoptotic activity in human leukemia U937 cells. ChemMedChem 2014;9:542–8.
   PubMed Web of Science ®Google Scholar
• Old DW, Preparation of alkyl or hydroxyalkyl-1- naphthamide or quinoline derivatives useful in treatment of glaucoma and ocular hypertension patent US Pat. 20150175586A1. 2015.
   Google Scholar
• Nainwal LM, Tasneem S, Akhtar W, et al. Green recipes to quinoline: a review. Eur J Med Chem 2019;164:121–70.
   PubMed Web of Science ®Google Scholar
• Chu XM, Wang C, Liu W, et al. Quinoline and quinolone dimers and their biological activities: an overview. Eur J Med Chem 2019;161:101–17.
   PubMed Web of Science ®Google Scholar
• Rivilli MJL, Turina AV, Bignante EA, et al. Synthesis and pharmacological evaluation of pyrazolo [4, 3-c] quinolinones as high affinity GABAA-R ligands and potential anxiolytics. Bioorg Med Chem 2018;26:3967–74.
   PubMed Web of Science ®Google Scholar
• Medapi B, Suryadevara P, Renuka J, et al. 4-Aminoquinoline derivatives as novel Mycobacterium tuberculosis GyrB inhibitors: structural optimization, synthesis and biological evaluation. Eur J Med Chem 2015;103:1–16.
   PubMed Web of Science ®Google Scholar
• Lawrence HR, Kazi A, Luo Y, et al. Synthesis and biological evaluation of naphthoquinone analogs as a novel class of proteasome inhibitors. Bioorg Med Chem 2010;18:5576–92.
   PubMed Web of Science ®Google Scholar
• Khalifah RG. The carbon dioxide hydration activity of carbonic anhydrase I. Stopflow kinetic studies on the native human isoenzymes B and C. J Biol Chem 1971;246:2561–73.
   PubMed Web of Science ®Google Scholar
• (a) Abo-Ashour MF, Eldehna WM, Nocentini A, et al. Novel hydrazido benzenesulfonamides-isatin conjugates: synthesis, carbonic anhydrase inhibitory activity and molecular modeling studies. Eur J Med Chem 2018;157:28–36.,
   PubMed Web of Science ®Google Scholar
  (b) Krall N, Pretto F, Decurtins W, et al. A small‐molecule drug conjugate for the treatment of carbonic anhydrase IX expressing tumors. Angew Chem Int Ed Engl 2014;53:4231–5.,
   PubMed Web of Science ®Google Scholar
  (c) Pacchiano F, Aggarwal M, Avvaru BS, et al. Selective hydrophobic pocket binding observed within the carbonic anhydrase II active site accommodate different 4-substituted-ureido-benzenesulfonamides and correlate to inhibitor potency. Chem Commun (Camb) 2010;46:8371–3.,
   PubMed Web of Science ®Google Scholar
  (d) Köhler K, Hillebrecht A, Schulze Wischeler J, et al. Saccharin inhibits carbonic anhydrases: possible explanation for its unpleasant metallic aftertaste. Angew Chem Int Ed Engl 2007;46:7697–9.
   PubMed Web of Science ®Google Scholar
• (a) Eldehna WM, Abo-Ashour MF, Berrino E, et al. SLC-0111 enaminone analogs, 3/4-(3-aryl-3-oxopropenyl) aminobenzenesulfonamides, as novel selective subnanomolar inhibitors of the tumor-associated carbonic anhydrase isoform IX. Bioorg Chem 2019;83:549–58.,
   PubMed Web of Science ®Google Scholar
  (b) Alterio V, Esposito D, Monti SM, et al. Crystal structure of the human carbonic anhydrase II adduct with 1-(4-sulfamoylphenyl-ethyl)-2,4,6-triphenylpyridinium perchlorate, a membrane-impermeant, isoform selective inhibitor. J Enzyme Inhib Med Chem 2018;33:151–7.,
   PubMed Web of Science ®Google Scholar
  (c) Innocenti A, Vullo D, Scozzafava A, et al. Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I–XIV with a series of substituted phenols including paracetamol and salicylic acid. Bioorg Med Chem 2008;16:7424–8.,
   PubMed Web of Science ®Google Scholar
  (d) Nocentini A, Bonardi A, Gratteri P, et al. Steroids interfere with human carbonic anhydrase activity by using alternative binding mechanisms. J Enzyme Inhib Med Chem 2018;33:1453–9.,
   PubMed Web of Science ®Google Scholar
  (e) Tars K, Vullo D, Kazaks A, et al. Sulfocoumarins (1,2-benzoxathiine-2,2-dioxides): a class of potent and isoform-selective inhibitors of tumor-associated carbonic anhydrases. J Med Chem 2013;56:293–300.
   PubMed Web of Science ®Google Scholar
• (a) Eldehna WM, Abo-Ashour MF, Nocentini A, et al. Enhancement of the tail hydrophobic interactions within the carbonic anhydrase IX active site via structural extension: design and synthesis of novel N-substituted isatins-SLC-0111 hybrids as carbonic anhydrase inhibitors and antitumor agents. Eur J Med Chem 2019;162:147–60.,
   PubMed Web of Science ®Google Scholar
  (b) Gul HI, Mete E, Taslimi P, et al. Synthesis, carbonic anhydrase I and II inhibition studies of the 1,3,5-trisubstituted-pyrazolines. J Enzyme Inhib Med Chem 2017;32:189–92.
   PubMed Web of Science ®Google Scholar
• (a) Eldehna WM, Nocentini A, Al-Rashood ST, et al. Tumor-associated carbonic anhydrase isoform IX and XII inhibitory properties of certain isatin-bearing sulfonamides endowed with in vitro anticancer activity towards colon cancer. Bioorg Med Chem 2018;81:425–32.,
   Web of Science ®Google Scholar
  (b) Pustenko A, Stepanovs D, Žalubovskis R, et al. 3H-1,2-benzoxathiepine 2,2-dioxides: a new class of isoform-selective carbonic anhydrase inhibitors. J Enzyme Inhib Med Chem 2017;32:767–75.
   PubMed Web of Science ®Google Scholar
• (a) Fares M, Eladwy RA, Nocentini A, et al. Synthesis of bulky-tailed sulfonamides incorporating pyrido[2,3-d][1,2,4]triazolo[4,3-a]pyrimidin-1(5H)-yl) moieties and evaluation of their carbonic anhydrases I, II, IV and IX inhibitory effects. Bioorg Med Chem 2017;25:2210–7.,
   PubMed Web of Science ®Google Scholar
  (b) Güzel-Akdemir Ö, Angeli A, Demir K, et al. Novel thiazolidinone-containing compounds, without the well-known sulfonamide zinc-binding group acting as human carbonic anhydrase IX inhibitors. J Enzyme Inhib Med Chem 2018;33:1299–308.,
   PubMed Web of Science ®Google Scholar
  (c) Ramya PVS, Angapelly S, Angeli A, et al. Discovery of curcumin inspired sulfonamide derivatives as a new class of carbonic anhydrase isoforms I, II, IX, and XII inhibitors. J Enzyme Inhib Med Chem 2017;32:1274–81.,
   PubMed Web of Science ®Google Scholar
  (d) Entezari Heravi Y, Sereshti H, Saboury AA, et al. 3D QSAR studies, pharmacophore modeling, and virtual screening of diarylpyrazole-benzenesulfonamide derivatives as a template to obtain new inhibitors, using human carbonic anhydrase II as a model protein. J Enzyme Inhib Med Chem 2017;32:688–700.,
   PubMed Web of Science ®Google Scholar
  (e) D'Ascenzio M, Guglielmi P, Carradori S, et al. Open saccharin-based secondary sulfonamides as potent and selective inhibitors of cancer-related carbonic anhydrase IX and XII isoforms. J Enzyme Inhib Med Chem 2017;32:51–9.,
   PubMed Web of Science ®Google Scholar
  (f) Krasavin M, Korsakov M, Ronzhina O, et al. Primary mono- and bis-sulfonamides obtained via regiospecific sulfochlorination of N-arylpyrazoles: inhibition profile against a panel of human carbonic anhydrases. J Enzyme Inhib Med Chem 2017;32:920–34.
   PubMed Web of Science ®Google Scholar